|Products||Total PSA IRMA Test|
|Company||Diagnostic Systems Laboratories, Inc.|
|Item||Total PSA IRMA Test|
|Description|| Prostate-Specific Antigen (PSA) derives its name from its first known site of origin, the prostate gland. The majority of PSA circulates bound to anti-chymotrypsin (PSA-ACT) and other compounds. Serum concentrations of PSA are elevated in patients with prostate cancer, benign prostatic hypertrophy (BPH) and prostatitis [1-3]. In addition, PSA serum levels appear to correlate with the volume and clinical stage of prostate cancer [1,4]. Selective determination of the various forms of PSA (i.e. free PSA, PSA-ACT complex and total PSA) may be useful to distinguish BPH from untreated prostate cancer. The ratio of free PSA to PSA-ACT is lower in untreated prostate cancer patients than in normal individuals or in patients with BPH. Thus, in patients with PSA in the 4 to 10 mg/L range (diagnostic gray zone), determination of free PSA fractions as a percentage of the total levels (i.e. the free PSA percentage) has been proposed as a means to improve discrimination between BPH and untreated prostate cancer in patients [1,3,5,6].
It has been found that PSA is not specific to the prostate. There are a number of non-prostatic sources of PSA, such as the periurethral glands, breast cancer tissues, breast fluids, amniotic fluid and other . Urinary PSA has also been measured in women with hyperandrogenic syndromes such as polycystic ovarian syndrome .
|Info|| Diagnostic Systems Laboratories, Inc.|
Customer Service: (800) 231-7970
Web site: http://www.dslabs.com